Restorative neurology

TRAZER® CHALLENGES NFL PLAYERS, COACHES, TRAINERS, AND MEDICAL STAFF TO TAKE THE 3 X 3 CHALLENGE TO SUPPORT THE BRAIN + BODY CONNECTION, BRAIN HEALTH & YOUTH SPORTS

Retrieved on: 
Thursday, February 9, 2023
AFL, Challenge, Biology, Acceleration, University, Stick, Injury, Athlete, Elite Performance, Bowl game, National Association Medical Staff Services, Super Bowl, Sport, Concussion, Siderian, Risk, NFL, Associate, Partnership, Health, AD, Prevalence, Talking stick, Mobile phone, Restorative neurology, Salt River Fields at Talking Stick

WESTLAKE, Ohio, Feb. 9, 2023 /PRNewswire/ -- TRAZER a leader in body movement technology designed for physical rehabilitation, strengthening, and enhancing athletic performance, is challenging NFL Teams to participate in the TRAZER 3 x 3 Challenge for an opportunity to win three (3) TRAZER systems for one (1) year. Aligned at the intersection of biology, technology, and data, TRAZER is used in healthcare, senior care, and elite sports performance for its predictive, prescriptive, and preventative features that help users rehabilitate faster and stronger regardless of their age or physical capability.

Key Points: 
  • The TRAZER 3 x 3 Challenge is open to players, coaches, trainers, and/or medical staff of every NFL team attending the 36th Annual Leigh Steinberg Super Bowl Party .
  • Participants will have an opportunity to complete the same predetermined activity up to three (3) times, each approximately 60-seconds.
  • The Neurologics booth will be in the Brain Lounge on the second level of the stadium at Salt River Fields at Talking Stick.
  • Details and the official rules of the 3 x 3 Challenge can be accessed online: https://university.trazer.com/3x3challenge-official-rules

Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Medical Devices, Other Health, Health, Clinical Trials, Patient, NRS, Clinic, Uncertainty, Minimally invasive spine surgery, World Neurosurgery, ODI, Multimedia, Back pain, Quality of life, European Economic Area, Physician, Disability, Pain, Restorative neurology, Risk, Multifidus muscle, Dentistry, Orthopedic surgery

Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ReActiv8-C study.

Key Points: 
  • Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ReActiv8-C study.
  • Patients implanted with ReActiv8 at Klinikum Itzehoe were consecutively included into this cohort if they presented with back pain 6 and no prior lumbar surgery.
  • I am excited to continue offering restorative neurostimulation with ReActiv8 for my patients with multifidus dysfunction resulting in chronic axial low back pain.
  • ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction.

Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™

Retrieved on: 
Wednesday, September 28, 2022
Health, Medical Devices, Surgery, Physical Therapy, Clinical Trials, Research, Science, Disability, European Economic Area, Risk, Hospital, Harvard Medical School, Principal, Population, Multifidus muscle, Forward-looking statement, Patient, Clinical trial, Physician, CEO, Pain, Spine, Uncertainty, Northwell Health, Research, Lenox Hill Hospital, Rehabilitation, Restorative neurology, Dentistry, Audit, Anesthesia, Brigham

ReActiv8 therapy has proven to maintain effectiveness long-term and provides this challenging patient population with a safe and restorative solution.

Key Points: 
  • ReActiv8 therapy has proven to maintain effectiveness long-term and provides this challenging patient population with a safe and restorative solution.
  • ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction.
  • Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical CLBP.
  • Mainstay Medical is headquartered in Dublin, Ireland, and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.

Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™

Retrieved on: 
Thursday, January 6, 2022
Research, Medical Devices, Surgery, Fitness & Nutrition, Clinical Trials, Physical Therapy, Alternative Medicine, General Health, Health, Science, Clinical trial, Harvard Medical School, United Kingdom, Multifidus muscle, Patient, Hospital, Forward-looking statement, Uncertainty, Data collection, CEO, FDA, Restorative neurology, Population, Pain, European Economic Area, IDE, Risk, Assistant, Rehabilitation, Pharmaceutical industry, Dentistry, Medical device, Anesthesia, Brigham, ReActiv8®, the ReActiv8-B Clinical Trial, Mainstay Medical, REACTIV8®, THE REACTIV8-B CLINICAL TRIAL, MAINSTAY MEDICAL

The ReActiv8-B trial patient cohort continues to be evaluated to generate additional data on longer-term efficacy.

Key Points: 
  • The ReActiv8-B trial patient cohort continues to be evaluated to generate additional data on longer-term efficacy.
  • ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction.
  • Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical CLBP.
  • Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.